Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05847569
Status:
RECRUITING
Last Update Posted:
2023-12-11
First Post:
2023-04-27
Brief Title:
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Organization Data
Organization:
Mayo Clinic
Class:
OTHER
Study ID:
MC210812
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Mayo Clinic
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None